This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.
Idaho medical cannabis measure nears ballot qualification (Newsletter: March 23, 2026)
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyMedical Cannabis AccessEpilepsyChronic PainPatient Care Why This MattersIdaho remains one of the last states...
Endocannabinoid System Research: CBD & Cortical Excitability
Clinical Takeaway In a controlled crossover trial in healthy adults, CBD at both low and high doses showed no direct effect on cortical excitability compared to placebo, suggesting its anti-seizure benefit may...
`Cannabinoids for Children: Clinical Evidence Reviewed`
Clinical Takeaway Current evidence on cannabinoids in pediatric patients spans 276 studies across multiple designs, capturing both plant-derived and pharmaceutical formulations used to treat medical conditions in children under 18. The research...
Endocannabinoid Research: Cannabinoids for Children Review
Clinical Takeaway Systematic review evidence supports cautious, condition-specific use of cannabinoids in pediatric patients, with the strongest data in epilepsy and certain pain or palliative conditions. Safety and efficacy profiles vary considerably...